However, the discovery of the overexpression and dependency on EGFR in HNSCC led to the development of the EGFR monoclonal antibody, cetuximab, which gained FDA approval in 2006 as a first-line agent in combination with radiation or as a single, second-line agent for non-metastatic HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.